{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:37:40Z","timestamp":1788845860870,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Justus-Liebig-Universit\u00e4t Gie\u00dfen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The decision to discontinue disease-modifying therapies (DMTs) in patients with multiple sclerosis (PwMS) is a critical clinical challenge. Historically, DMTs were discontinued due to side effects, treatment limitations, or progression to secondary progressive MS. However, advancements in MS therapies, particularly high-efficacy DMTs (HE-DMTs) and the increased knowledge on disease courses and phenotypes have resulted in more personalized treatment approaches and introduced discussion on scheduled DMT discontinuation. This review explores the current evidence on DMT discontinuation, focusing on its implications for aging populations and the interplay between cardiovascular diseases (CVD) and MS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Current evidence and interplay with CVD<\/jats:title>\n            <jats:p>Randomized trials such as DISCOMS and DOT-MS have provided insights into discontinuing DMTs in stable patients. In summary, both randomized clinical trials highlight the risk of disease reactivation following treatment discontinuation. Due to the limited sample size, neither study was able to conduct subgroup analyses based on age groups. Additionally, DOT-MS was terminated prematurely, direct comparisons with other studies should be avoided. While older studies and observational data (e.g., OFSEP) have shown relapse risks associated with discontinuation, particularly for drugs like natalizumab and fingolimod, there is limited data on HE-DMT discontinuation outcomes. Comorbidities, particularly CVDs, further complicate decisions regarding the continuation of DMTs in older adults. MS patients bear a higher burden of CVD, which is also associated with unfavorable disease courses. While optimizing cardiovascular risk profiles appears advisable, it remains unclear whether DMTs themselves have a positive impact on CVDs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Given the complexities associated with discontinuing DMTs in MS patients, it is essential to balance the avoidance of polypharmacy with the potential risks of disease reactivation and the impact of comorbidities, especially CVDs, on disease progression. The interplay between MS and CVD highlights the importance of a holistic risk assessment when considering DMT discontinuation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s42466-025-00379-y","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T23:02:21Z","timestamp":1745190141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis"],"prefix":"10.1186","volume":"7","author":[{"given":"Anne","family":"Mrochen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5171-4845","authenticated-orcid":false,"given":"Steffen","family":"Pfeuffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"9","key":"379_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11910-024-01355-w","volume":"24","author":"RH Gross","year":"2024","unstructured":"Gross, R. H., & Corboy, J. (2024). De-escalation and discontinuation of disease-modifying therapies in multiple sclerosis. Current Neurology and Neuroscience Reports, 24(9), 341\u2013353. https:\/\/doi.org\/10.1007\/s11910-024-01355-w","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"10","key":"379_CR2","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.1007\/s00415-024-12584-x","volume":"271","author":"K Selmaj","year":"2024","unstructured":"Selmaj, K., Hartung, H. P., Mycko, M. P., Selmaj, I., & Cross, A. H. (2024). MS treatment de-escalation: Review and commentary. Journal of Neurology, 271(10), 6426\u20136438. https:\/\/doi.org\/10.1007\/s00415-024-12584-x","journal-title":"Journal of Neurology"},{"key":"379_CR3","doi-asserted-by":"publisher","first-page":"Cd005181","DOI":"10.1002\/14651858.CD005181.pub3","volume":"1","author":"L La Mantia","year":"2012","unstructured":"La Mantia, L., Vacchi, L., Di Pietrantonj, C., Ebers, G., Rovaris, M., Fredrikson, S., & Filippini, G. (2012). Interferon beta for secondary progressive multiple sclerosis. Cochrane Database of Systematic Reviews, 1, Cd005181. https:\/\/doi.org\/10.1002\/14651858.CD005181.pub3","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 2","key":"379_CR4","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1007\/s10072-009-0142-7","volume":"30","author":"V Martinelli","year":"2009","unstructured":"Martinelli, V., Radaelli, M., Straffi, L., Rodegher, M., & Comi, G. (2009). Mitoxantrone: Benefits and risks in multiple sclerosis patients. Neurological Sciences, 30(Suppl 2), S167-170. https:\/\/doi.org\/10.1007\/s10072-009-0142-7","journal-title":"Neurological Sciences"},{"issue":"8","key":"379_CR5","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/09546634.2018.1467539","volume":"29","author":"M Maurelli","year":"2018","unstructured":"Maurelli, M., Bergamaschi, R., Antonini, A., Fargnoli, M. C., Puma, E., Mallucci, G., Totaro, R., & Girolomoni, G. (2018). Interferon-beta injection site reactions in patients with multiple sclerosis. Journal of Dermatological Treatment, 29(8), 831\u2013834. https:\/\/doi.org\/10.1080\/09546634.2018.1467539","journal-title":"Journal of Dermatological Treatment"},{"issue":"6","key":"379_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","volume":"91","author":"H Butzkueven","year":"2020","unstructured":"Butzkueven, H., Kappos, L., Wiendl, H., Trojano, M., Spelman, T., Chang, I., Kasliwal, R., Jaitly, S., Campbell, N., Ho, P. R., & Licata, S. (2020). Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 91(6), 660\u2013668. https:\/\/doi.org\/10.1136\/jnnp-2019-322326","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"4","key":"379_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He, A., Merkel, B., Brown, J. W., Ryerson, L. Z., Kister, I., Malpas, C. B., Sharmin, S., Horakova, D., Havrdova, E. K., Spelman, T., & Izquierdo, G. (2020). Timing of high-efficacy therapy for multiple sclerosis: A retrospective observational cohort study. Lancet Neurology, 19(4), 307\u2013316. https:\/\/doi.org\/10.1016\/s1474-4422(20)30067-3","journal-title":"Lancet Neurology"},{"issue":"10","key":"379_CR8","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","volume":"78","author":"T Spelman","year":"2021","unstructured":"Spelman, T., Magyari, M., Piehl, F., Svenningsson, A., Rasmussen, P. V., Kant, M., Sellebjerg, F., Joensen, H., Hillert, J., & Lycke, J. (2021). Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: Data from 2 different national strategies. JAMA Neurology, 78(10), 1197\u20131204. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2738","journal-title":"JAMA Neurology"},{"issue":"7","key":"379_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132033","volume":"10","author":"E Leray","year":"2015","unstructured":"Leray, E., Vukusic, S., Debouverie, M., Clanet, M., Brochet, B., S\u00e8ze, J. D., Z\u00e9phir, H., Defer, G., Lebrun-Frenay, C., Moreau, T., & Clavelou, P. (2015). Excess mortality in patients with multiple sclerosis starts at 20 years from clinical onset: Data from a large-scale french observational study. PLoS ONE, 10(7), e0132033. https:\/\/doi.org\/10.1371\/journal.pone.0132033","journal-title":"PLoS ONE"},{"issue":"8","key":"379_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","volume":"88","author":"HMB Lunde","year":"2017","unstructured":"Lunde, H. M. B., Assmus, J., Myhr, K.-M., B\u00f8, L., & Grytten, N. (2017). Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study. Journal of Neurology, Neurosurgery & Psychiatry, 88(8), 621\u2013625. https:\/\/doi.org\/10.1136\/jnnp-2016-315238","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"6","key":"379_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/1352458516634871","volume":"22","author":"SA Sanai","year":"2016","unstructured":"Sanai, S. A., Saini, V., Benedict, R. H., Zivadinov, R., Teter, B. E., Ramanathan, M., & Weinstock-Guttman, B. (2016). Aging and multiple sclerosis. Multiple Sclerosis Journal, 22(6), 717\u2013725. https:\/\/doi.org\/10.1177\/1352458516634871","journal-title":"Multiple Sclerosis Journal"},{"issue":"10","key":"379_CR12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jamaneurol.2024.2876","volume":"81","author":"J Graf","year":"2024","unstructured":"Graf, J., Akmatov, M. K., Meuth, S. G., Tremlett, H., & Holstiege, J. (2024). Updated multiple sclerosis incidence, 2015\u20132022. JAMA Neurology, 81(10), 1100\u20131102. https:\/\/doi.org\/10.1001\/jamaneurol.2024.2876","journal-title":"JAMA Neurology"},{"issue":"9","key":"379_CR13","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin, F. D., H\u00e4ring, D. A., Ganjgahi, H., Ocampo, A., Hatami, F., \u010cuklina, J., Aarden, P., Dahlke, F., Arnold, D. L., Wiendl, H., & Chitnis, T. (2022). How patients with multiple sclerosis acquire disability. Brain, 145(9), 3147\u20133161. https:\/\/doi.org\/10.1093\/brain\/awac016","journal-title":"Brain"},{"issue":"9","key":"379_CR14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., & Hauser, S. L. (2020). Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology, 77(9), 1132\u20131140. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1568","journal-title":"JAMA Neurology"},{"key":"379_CR15","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3389\/fneur.2020.00851","volume":"11","author":"M Magyari","year":"2020","unstructured":"Magyari, M., & Sorensen, P. S. (2020). Comorbidity in multiple sclerosis. Frontiers in Neurology, 11, 851. https:\/\/doi.org\/10.3389\/fneur.2020.00851","journal-title":"Frontiers in Neurology"},{"issue":"2","key":"379_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna, G., Alping, P., Burman, J., Fink, K., Fogdell-Hahn, A., Gunnarsson, M., Hillert, J., Langer-Gould, A., Lycke, J., Nilsson, P., & Salzer, J. (2020). Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology, 77(2), 184\u2013191. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3365","journal-title":"JAMA Neurology"},{"issue":"Suppl 1","key":"379_CR17","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/s1386-6532(10)70002-0","volume":"48","author":"AA Gershon","year":"2010","unstructured":"Gershon, A. A., Gershon, M. D., Breuer, J., Levin, M. J., Oaklander, A. L., & Griffiths, P. D. (2010). Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. Journal of Clinical Virology, 48(Suppl 1), S2-7. https:\/\/doi.org\/10.1016\/s1386-6532(10)70002-0","journal-title":"Journal of Clinical Virology"},{"key":"379_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.763433","volume":"12","author":"G Giovannoni","year":"2021","unstructured":"Giovannoni, G., Coyle, P. K., Vermersch, P., Walker, B., Aldridge, J., Nolting, A., Galazka, A., Lemieux, C., & Leist, T. P. (2021). Integrated lymphopenia analysis in younger and older patients with multiple sclerosis treated with cladribine tablets. Frontiers in Immunology, 12, 763433. https:\/\/doi.org\/10.3389\/fimmu.2021.763433","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"379_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H. P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., & Traboulsee, A. (2017). Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. The New England Journal of Medicine, 376(3), 221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"379_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., De Seze, J., Giovannoni, G., Hartung, H. P., Hemmer, B., & Lublin, F. (2017). Ocrelizumab versus placebo in primary progressive multiple sclerosis. The New England Journal of Medicine, 376(3), 209\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa1606468","journal-title":"The New England Journal of Medicine"},{"key":"379_CR21","doi-asserted-by":"crossref","unstructured":"SL Hauser, L. K., Montalban, X., Chognot, C., Pasquarelli, N., Punia, V. E. I., El Azzouzi, B., Wolinsky, J. S. (2024). Safety of ocrelizumab in multiple sclerosis: Up to 11 years of updated analysis in patients with relapsing and progressive multiple sclerosis.","DOI":"10.1016\/j.msard.2023.105308"},{"issue":"6","key":"379_CR22","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s00415-024-12286-4","volume":"271","author":"Y Goereci","year":"2024","unstructured":"Goereci, Y., Ellenberger, D., Rommer, P., Dunkl, V., Golla, H., Zettl, U., Stahmann, A., & Warnke, C. (2024). Persons with multiple sclerosis older than 55 years: An analysis from the German MS registry. Journal of Neurology, 271(6), 3409\u20133416. https:\/\/doi.org\/10.1007\/s00415-024-12286-4","journal-title":"Journal of Neurology"},{"issue":"7","key":"379_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","volume":"80","author":"M Hittle","year":"2023","unstructured":"Hittle, M., Culpepper, W. J., Langer-Gould, A., Marrie, R. A., Cutter, G. R., Kaye, W. E., Wagner, L., Topol, B., LaRocca, N. G., Nelson, L. M., & Wallin, M. T. (2023). Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region. JAMA Neurology, 80(7), 693\u2013701. https:\/\/doi.org\/10.1001\/jamaneurol.2023.1135","journal-title":"JAMA Neurology"},{"key":"379_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.4164","author":"EM Coerver","year":"2024","unstructured":"Coerver, E. M., Fung, W. H., De Beukelaar, J., Bouvy, W. H., Canta, L. R., Gerlach, O. H., Hoitsma, E., Hoogervorst, E. L., De Jong, B. A., Kalkers, N. F., & Van Kempen, Z. L. (2024). Discontinuation of first-line disease-modifying therapy in patients with stable multiple sclerosis: The DOT-MS randomized clinical trial. JAMA Neurology. https:\/\/doi.org\/10.1001\/jamaneurol.2024.4164","journal-title":"JAMA Neurology"},{"issue":"7","key":"379_CR25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/s1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy, J. R., Fox, R. J., Kister, I., Cutter, G. R., Morgan, C. J., Seale, R., Engebretson, E., Gustafson, T., Miller, A. E., Bourdette, D., & Yadav, V. (2023). Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): A multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurology, 22(7), 568\u2013577. https:\/\/doi.org\/10.1016\/s1474-4422(23)00154-0","journal-title":"Lancet Neurology"},{"issue":"5","key":"379_CR26","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/ene.14705","volume":"28","author":"G Bsteh","year":"2021","unstructured":"Bsteh, G., Hegen, H., Riedl, K., Altmann, P., Auer, M., Berek, K., Di Pauli, F., Ehling, R., Kornek, B., Monschein, T., & Rinner, W. (2021). Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score. European Journal of Neurology, 28(5), 1609\u20131616. https:\/\/doi.org\/10.1111\/ene.14705","journal-title":"European Journal of Neurology"},{"issue":"17","key":"379_CR27","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant, A., Day, G. S., Marrie, R. A., Rabinstein, A., Cree, B. A., Gronseth, G. S., Haboubi, M., Halper, J., Hosey, J. P., Jones, D. E., & Lisak, R. (2018). Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology, 90(17), 777\u2013788. https:\/\/doi.org\/10.1212\/WNL.0000000000005347","journal-title":"Neurology"},{"issue":"2","key":"379_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.7224\/1537-2073.2018-107","volume":"22","author":"KB Knox","year":"2020","unstructured":"Knox, K. B., Saini, A., & Levin, M. C. (2020). The dilemma of when to stop disease-modifying therapy in multiple sclerosis: A narrative review and Canadian regional reimbursement policies. International Journal of MS Care, 22(2), 75\u201384. https:\/\/doi.org\/10.7224\/1537-2073.2018-107","journal-title":"International Journal of MS Care"},{"issue":"2","key":"379_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., & Hartung, H. P. (2018). ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 24(2), 96\u2013120. https:\/\/doi.org\/10.1177\/1352458517751049","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"379_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","volume":"4","author":"M Lo Re","year":"2015","unstructured":"Lo Re, M., Capobianco, M., Ragonese, P., Realmuto, S., Malucchi, S., Berchialla, P., Salemi, G., & Bertolotto, A. (2015). Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): A retrospective study from two Italian MS Centers. Neurology and Therapy, 4(2), 147\u2013157. https:\/\/doi.org\/10.1007\/s40120-015-0038-9","journal-title":"Neurology and Therapy"},{"issue":"9","key":"379_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jnnp-2015-312221","volume":"87","author":"B Weinstock-Guttman","year":"2016","unstructured":"Weinstock-Guttman, B., Hagemeier, J., Kavak, K. S., Saini, V., Patrick, K., Ramasamy, D. P., Nadeem, M., Carl, E., Hojnacki, D., & Zivadinov, R. (2016). Randomised natalizumab discontinuation study: Taper protocol may prevent disease reactivation. Journal of Neurology, Neurosurgery and Psychiatry, 87(9), 937\u2013943. https:\/\/doi.org\/10.1136\/jnnp-2015-312221","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"6","key":"379_CR32","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.24651","volume":"79","author":"P Alping","year":"2016","unstructured":"Alping, P., Frisell, T., Novakova, L., Islam-Jakobsson, P., Salzer, J., Bj\u00f6rck, A., Axelsson, M., Malmestr\u00f6m, C., Fink, K., Lycke, J., & Svenningsson, A. (2016). Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology, 79(6), 950\u2013958. https:\/\/doi.org\/10.1002\/ana.24651","journal-title":"Annals of Neurology"},{"issue":"1","key":"379_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7224\/1537-2073.2015-032","volume":"19","author":"G Birnbaum","year":"2017","unstructured":"Birnbaum, G. (2017). Stopping disease-modifying therapy in nonrelapsing multiple sclerosis: Experience from a clinical practice. International Journal of MS Care, 19(1), 11\u201314. https:\/\/doi.org\/10.7224\/1537-2073.2015-032","journal-title":"International Journal of MS Care"},{"issue":"5","key":"379_CR34","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","volume":"81","author":"G Jouvenot","year":"2024","unstructured":"Jouvenot, G., Courbon, G., Lefort, M., Rollot, F., Casey, R., Le Page, E., Michel, L., Edan, G., de Seze, J., Kremer, L., & Bigaut, K. (2024). High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS. JAMA Neurology, 81(5), 490\u2013498. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0395","journal-title":"JAMA Neurology"},{"key":"379_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001035","author":"L Rolfes","year":"2021","unstructured":"Rolfes, L., Pawlitzki, M., Pfeuffer, S., Nelke, C., Lux, A., Pul, R., Kleinschnitz, C., Kleinschnitz, K., Rogall, R., Pape, K., & Bittner, S. (2021). Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurology Neuroimmunology & Neuroinflammation. https:\/\/doi.org\/10.1212\/nxi.0000000000001035","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"key":"379_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200064","author":"T Ziemssen","year":"2023","unstructured":"Ziemssen, T., Bhan, V., Chataway, J., Chitnis, T., Campbell Cree, B. A., Havrdova, E. K., Kappos, L., Labauge, P., Miller, A., Nakahara, J., & Oreja-Guevara, C. (2023). Secondary progressive multiple sclerosis: A review of clinical characteristics, definition, prognostic tools, and disease-modifying therapies. Neurology Neuroimmunology & Neuroinflammation. https:\/\/doi.org\/10.1212\/nxi.0000000000200064","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"10","key":"379_CR37","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1177\/13524585241266180","volume":"30","author":"L Prosperini","year":"2024","unstructured":"Prosperini, L., Ruggieri, S., Haggiag, S., Tortorella, C., & Gasperini, C. (2024). Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context. Multiple Sclerosis Journal, 30(10), 1309\u20131321. https:\/\/doi.org\/10.1177\/13524585241266180","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"379_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamaneurol.2023.4455","volume":"81","author":"P Iaffaldano","year":"2024","unstructured":"Iaffaldano, P., Portaccio, E., Lucisano, G., Simone, M., Manni, A., Guerra, T., Paolicelli, D., Betti, M., De Meo, E., Past\u00f2, L., & Razzolini, L. (2024). Multiple sclerosis progression and relapse activity in children. JAMA Neurology, 81(1), 50\u201358. https:\/\/doi.org\/10.1001\/jamaneurol.2023.4455","journal-title":"JAMA Neurology"},{"key":"379_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001094","author":"M Eschborn","year":"2021","unstructured":"Eschborn, M., Pawlitzki, M., Wirth, T., Nelke, C., Pfeuffer, S., Schulte-Mecklenbeck, A., Lohmann, L., Rolfes, L., Pape, K., Eveslage, M., & Bittner, S. (2021). evaluation of age-dependent immune signatures in patients with multiple sclerosis. Neurology Neuroimmunology & Neuroinflammation. https:\/\/doi.org\/10.1212\/NXI.0000000000001094","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"1\u20132","key":"379_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jns.2008.06.032","volume":"274","author":"E Meinl","year":"2008","unstructured":"Meinl, E., Krumbholz, M., Derfuss, T., Junker, A., & Hohlfeld, R. (2008). Compartmentalization of inflammation in the CNS: A major mechanism driving progressive multiple sclerosis. Journal of the Neurological Sciences, 274(1\u20132), 42\u201344. https:\/\/doi.org\/10.1016\/j.jns.2008.06.032","journal-title":"Journal of the Neurological Sciences"},{"key":"379_CR41","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200167","author":"G Bose","year":"2023","unstructured":"Bose, G., Healy, B. C., Saxena, S., Saleh, F., Glanz, B. I., Bakshi, R., Weiner, H. L., & Chitnis, T. (2023). Increasing neurofilament and glial fibrillary acidic protein after treatment discontinuation predicts multiple sclerosis disease activity. Neurology Neuroimmunology & Neuroinflammation. https:\/\/doi.org\/10.1212\/nxi.0000000000200167","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"key":"379_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104706","volume":"74","author":"EM Coerver","year":"2023","unstructured":"Coerver, E. M., Bourass, A., Wessels, M. H., van Kempen, Z. L., Jasperse, M. M., Tonino, B. A., Barkhof, F., Mostert, J., Uitdehaag, B. M., Killestein, J., & Strijbis, E. M. (2023). Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 74, 104706. https:\/\/doi.org\/10.1016\/j.msard.2023.104706","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"5","key":"379_CR43","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200279","volume":"11","author":"L Husseini","year":"2024","unstructured":"Husseini, L., Jung, J., Boess, N., Kruse, N., Nessler, S., Stadelmann, C., Metz, I., Haupts, M., & Weber, M. S. (2024). Neurofilament light chain serum levels mirror age and disability in secondary progressive multiple sclerosis: A cross-sectional study. Neurology Neuroimmunology & Neuroinflammation, 11(5), e200279. https:\/\/doi.org\/10.1212\/nxi.0000000000200279","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"1","key":"379_CR44","doi-asserted-by":"publisher","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","volume":"8","author":"A Abdelhak","year":"2018","unstructured":"Abdelhak, A., Huss, A., Kassubek, J., Tumani, H., & Otto, M. (2018). Serum GFAP as a biomarker for disease severity in multiple sclerosis. Scientific Reports, 8(1), 14798. https:\/\/doi.org\/10.1038\/s41598-018-33158-8","journal-title":"Scientific Reports"},{"issue":"1","key":"379_CR45","doi-asserted-by":"publisher","first-page":"10923","DOI":"10.1038\/s41598-020-67934-2","volume":"10","author":"X Ayrignac","year":"2020","unstructured":"Ayrignac, X., Le Bars, E., Duflos, C., Hirtz, C., Maleska Maceski, A., Carra-Dalliere, C., Charif, M., Pinna, F., Prin, P., Menjot de Champfleur, N., & Deverdun, J. (2020). Serum GFAP in multiple sclerosis: Correlation with disease type and MRI markers of disease severity. Scientific Reports, 10(1), 10923. https:\/\/doi.org\/10.1038\/s41598-020-67934-2","journal-title":"Scientific Reports"},{"issue":"13","key":"379_CR46","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1177\/1352458518800815","volume":"25","author":"BL Conway","year":"2019","unstructured":"Conway, B. L., Zeydan, B., Uyguno\u011flu, U., Novotna, M., Siva, A., Pittock, S. J., Atkinson, E. J., Rodriguez, M., & Kantarci, O. H. (2019). Age is a critical determinant in recovery from multiple sclerosis relapses. Multiple Sclerosis Journal, 25(13), 1754\u20131763. https:\/\/doi.org\/10.1177\/1352458518800815","journal-title":"Multiple Sclerosis Journal"},{"issue":"11","key":"379_CR47","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1093\/brain\/awae251","volume":"147","author":"M Filippi","year":"2024","unstructured":"Filippi, M., Preziosa, P., Barkhof, F., Ciccarelli, O., Cossarizza, A., De Stefano, N., Gasperini, C., Geraldes, R., Granziera, C., Haider, L., & Lassmann, H. (2024). The ageing central nervous system in multiple sclerosis: The imaging perspective. Brain, 147(11), 3665\u20133680. https:\/\/doi.org\/10.1093\/brain\/awae251","journal-title":"Brain"},{"issue":"2","key":"379_CR48","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000209574","volume":"103","author":"S Pfeuffer","year":"2024","unstructured":"Pfeuffer, S., Wolff, S., Aslan, D., Rolfes, L., Korsen, M., Pawlitzki, M., Albrecht, P., Havla, J., Huttner, H. B., Kleinschnitz, C., & Meuth, S. G. (2024). Association of clinical relapses with disease outcomes in multiple sclerosis patients older than 50 years. Neurology, 103(2), e209574. https:\/\/doi.org\/10.1212\/wnl.0000000000209574","journal-title":"Neurology"},{"issue":"6","key":"379_CR49","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.msard.2014.08.005","volume":"3","author":"FD Lublin","year":"2014","unstructured":"Lublin, F. D., Cutter, G., Giovannoni, G., Pace, A., Campbell, N. R., & Belachew, S. (2014). Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Multiple Sclerosis and Related Disorders, 3(6), 705\u2013711. https:\/\/doi.org\/10.1016\/j.msard.2014.08.005","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2","key":"379_CR50","doi-asserted-by":"publisher","first-page":"205521732110155","DOI":"10.1177\/20552173211015503","volume":"7","author":"MG Sotiropoulos","year":"2021","unstructured":"Sotiropoulos, M. G., Lokhande, H., Healy, B. C., Polgar-Turcsanyi, M., Glanz, B. I., Bakshi, R., Weiner, H. L., & Chitnis, T. (2021). Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 7(2), 20552173211015504. https:\/\/doi.org\/10.1177\/20552173211015503","journal-title":"Multiple Sclerosis Journal - Experimental, Translational and Clinical"},{"issue":"3","key":"379_CR51","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/brain\/aww258","volume":"140","author":"J Correale","year":"2017","unstructured":"Correale, J., Gait\u00e1n, M. I., Ysrraelit, M. C., & Fiol, M. P. (2017). Progressive multiple sclerosis: From pathogenic mechanisms to treatment. Brain, 140(3), 527\u2013546. https:\/\/doi.org\/10.1093\/brain\/aww258","journal-title":"Brain"},{"issue":"9","key":"379_CR52","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1093\/brain\/awaa231","volume":"143","author":"I Roos","year":"2020","unstructured":"Roos, I., Leray, E., Frascoli, F., Casey, R., Brown, J. W., Horakova, D., Havrdova, E. K., Trojano, M., Patti, F., Izquierdo, G., & Eichau, S. (2020). Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 143(9), 2742\u20132756. https:\/\/doi.org\/10.1093\/brain\/awaa231","journal-title":"Brain"},{"issue":"3","key":"379_CR53","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208006","volume":"102","author":"HS Ng","year":"2024","unstructured":"Ng, H. S., Zhu, F., Zhao, Y., Yao, S., Lu, X., Ekuma, O., Evans, C., Fisk, J. D., Marrie, R. A., & Tremlett, H. (2024). Adverse events associated with disease-modifying drugs for multiple sclerosis. Neurology, 102(3), e208006. https:\/\/doi.org\/10.1212\/WNL.0000000000208006","journal-title":"Neurology"},{"issue":"11","key":"379_CR54","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1177\/1352458520979304","volume":"27","author":"CK Chan","year":"2021","unstructured":"Chan, C. K., Tian, F., Pimentel Maldonado, D., Mowry, E. M., & Fitzgerald, K. C. (2021). Depression in multiple sclerosis across the adult lifespan. Multiple Sclerosis Journal, 27(11), 1771\u20131780. https:\/\/doi.org\/10.1177\/1352458520979304","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"379_CR55","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/13524585231221415","volume":"30","author":"E Framke","year":"2024","unstructured":"Framke, E., Thygesen, L. C., Malmborg, M., Schou, M., Sellebjerg, F., & Magyari, M. (2024). Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark. Multiple Sclerosis Journal, 30(2), 184\u2013191. https:\/\/doi.org\/10.1177\/13524585231221415","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"379_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/13524585221122207","volume":"29","author":"A Chertcoff","year":"2023","unstructured":"Chertcoff, A., Ng, H. S., Zhu, F., Zhao, Y., & Tremlett, H. (2023). Polypharmacy and multiple sclerosis: A population-based study. Multiple Sclerosis Journal, 29(1), 107\u2013118. https:\/\/doi.org\/10.1177\/13524585221122207","journal-title":"Multiple Sclerosis Journal"},{"issue":"14","key":"379_CR57","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1212\/WNL.0000000000002543","volume":"86","author":"T Zhang","year":"2016","unstructured":"Zhang, T., Tremlett, H., Leung, S., Zhu, F., Kingwell, E., Fisk, J. D., Bhan, V., Campbell, T. L., Stadnyk, K., Yu, B. N., & Marrie, R. A. (2016). Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology, 86(14), 1287\u20131295. https:\/\/doi.org\/10.1212\/WNL.0000000000002543","journal-title":"Neurology"},{"issue":"13","key":"379_CR58","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","volume":"74","author":"RA Marrie","year":"2010","unstructured":"Marrie, R. A., Rudick, R., Horwitz, R., Cutter, G., Tyry, T., Campagnolo, D., & Vollmer, T. (2010). Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology, 74(13), 1041\u20131047. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d6b125","journal-title":"Neurology"},{"issue":"11","key":"379_CR59","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamaneurol.2024.2920","volume":"81","author":"A Salter","year":"2024","unstructured":"Salter, A., Lancia, S., Kowalec, K., Fitzgerald, K. C., & Marrie, R. A. (2024). Comorbidity and disease activity in multiple sclerosis. JAMA Neurology, 81(11), 1170\u20131177. https:\/\/doi.org\/10.1001\/jamaneurol.2024.2920","journal-title":"JAMA Neurology"},{"key":"379_CR60","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M., & Bielekova, B. (2017). Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Frontiers in Neurology, 8, 577. https:\/\/doi.org\/10.3389\/fneur.2017.00577","journal-title":"Frontiers in Neurology"},{"key":"379_CR61","doi-asserted-by":"publisher","first-page":"1197212","DOI":"10.3389\/fneur.2023.1197212","volume":"14","author":"G Macaron","year":"2023","unstructured":"Macaron, G., Larochelle, C., Arbour, N., Galmard, M., Girard, J. M., Prat, A., & Duquette, P. (2023). Impact of aging on treatment considerations for multiple sclerosis patients. Frontiers in Neurology, 14, 1197212. https:\/\/doi.org\/10.3389\/fneur.2023.1197212","journal-title":"Frontiers in Neurology"},{"issue":"6","key":"379_CR62","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208051","volume":"102","author":"EF Mouresan","year":"2024","unstructured":"Mouresan, E. F., Mentesidou, E., Berglund, A., McKay, K. A., Hillert, J., & Iacobaeus, E. (2024). Clinical characteristics and long-term outcomes of late-onset multiple sclerosis. Neurology, 102(6), e208051. https:\/\/doi.org\/10.1212\/WNL.0000000000208051","journal-title":"Neurology"},{"issue":"8","key":"379_CR63","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1007\/s00415-023-11739-6","volume":"270","author":"S Ciardullo","year":"2023","unstructured":"Ciardullo, S., Muraca, E., Bianconi, E., Ronchetti, C., Cannistraci, R., Rossi, L., Perra, S., Zerbini, F., & Perseghin, G. (2023). Serum neurofilament light chain levels are associated with all-cause mortality in the general US population. Journal of Neurology, 270(8), 3830\u20133838. https:\/\/doi.org\/10.1007\/s00415-023-11739-6","journal-title":"Journal of Neurology"},{"issue":"1","key":"379_CR64","doi-asserted-by":"publisher","first-page":"26117","DOI":"10.1038\/s41598-024-77446-y","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu, J., & Zhang, Y. (2024). Serum neurofilament light chain: A novel biomarker for cardiovascular diseases in individuals without hypertension. Scientific Reports, 14(1), 26117. https:\/\/doi.org\/10.1038\/s41598-024-77446-y","journal-title":"Scientific Reports"},{"issue":"1","key":"379_CR65","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu, Z., Liang, Q., Ren, Y., Guo, C., Ge, X., Wang, L., Cheng, Q., Luo, P., Zhang, Y., & Han, X. (2023). Immunosenescence: Molecular mechanisms and diseases. Signal Transduction and Targeted Therapy, 8(1), 200. https:\/\/doi.org\/10.1038\/s41392-023-01451-2","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"379_CR66","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/ene.13769","volume":"26","author":"D Jakimovski","year":"2019","unstructured":"Jakimovski, D., Gandhi, S., Paunkoski, I., Bergsland, N., Hagemeier, J., Ramasamy, D. P., Hojnacki, D., Kolb, C., Benedict, R. H., Weinstock-Guttman, B., & Zivadinov, R. (2019). Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: A 5-year longitudinal study. European Journal of Neurology, 26(1), 87-e88. https:\/\/doi.org\/10.1111\/ene.13769","journal-title":"European Journal of Neurology"},{"key":"379_CR67","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000616","author":"CJ Azevedo","year":"2019","unstructured":"Azevedo, C. J., Cen, S. Y., Jaberzadeh, A., Zheng, L., Hauser, S. L., & Pelletier, D. (2019). Contribution of normal aging to brain atrophy in MS. Neurology Neuroimmunology & Neuroinflammation. https:\/\/doi.org\/10.1212\/nxi.0000000000000616","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"7","key":"379_CR68","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1001\/jamaneurol.2020.0664","volume":"77","author":"R Palladino","year":"2020","unstructured":"Palladino, R., Marrie, R. A., Majeed, A., & Chataway, J. (2020). Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England. JAMA Neurology, 77(7), 820\u2013828. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0664","journal-title":"JAMA Neurology"},{"issue":"8","key":"379_CR69","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/eurheartj\/ehu403","volume":"36","author":"JC Mason","year":"2015","unstructured":"Mason, J. C., & Libby, P. (2015). Cardiovascular disease in patients with chronic inflammation: Mechanisms underlying premature cardiovascular events in rheumatologic conditions. European Heart Journal, 36(8), 482\u2013489c. https:\/\/doi.org\/10.1093\/eurheartj\/ehu403","journal-title":"European Heart Journal"},{"issue":"6","key":"379_CR70","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ana.24807","volume":"80","author":"K G\u00f6bel","year":"2016","unstructured":"G\u00f6bel, K., Kraft, P., Pankratz, S., Gross, C. C., Korsukewitz, C., Kwiecien, R., Mesters, R., Kehrel, B. E., Wiendl, H., Kleinschnitz, C., & Meuth, S. G. (2016). Prothrombin and factor X are elevated in multiple sclerosis patients. Annals of Neurology, 80(6), 946\u2013951. https:\/\/doi.org\/10.1002\/ana.24807","journal-title":"Annals of Neurology"},{"issue":"9","key":"379_CR71","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1182\/blood-2018-11-882993","volume":"133","author":"SP Jackson","year":"2019","unstructured":"Jackson, S. P., Darbousset, R., & Schoenwaelder, S. M. (2019). Thromboinflammation: Challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood, 133(9), 906\u2013918. https:\/\/doi.org\/10.1182\/blood-2018-11-882993","journal-title":"Blood"},{"issue":"7855","key":"379_CR72","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby, P. (2021). The changing landscape of atherosclerosis. Nature, 592(7855), 524\u2013533. https:\/\/doi.org\/10.1038\/s41586-021-03392-8","journal-title":"Nature"},{"key":"379_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021082","author":"H Zhang","year":"2024","unstructured":"Zhang, H., & Dhalla, N. S. (2024). The role of pro-inflammatory cytokines in the pathogenesis of cardiovascular disease. Journal of the Neurological Sciences. https:\/\/doi.org\/10.3390\/ijms25021082","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"379_CR74","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/jnnp-2022-329685","volume":"94","author":"I Lutfullin","year":"2023","unstructured":"Lutfullin, I., Eveslage, M., Bittner, S., Antony, G., Flaskamp, M., Luessi, F., Salmen, A., Gisevius, B., Klotz, L., Korsukewitz, C., & Berthele, A. (2023). Association of obesity with disease outcome in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 94(1), 57\u201361. https:\/\/doi.org\/10.1136\/jnnp-2022-329685","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1","key":"379_CR75","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200334","volume":"12","author":"J Wu","year":"2025","unstructured":"Wu, J., Alfredsson, L., Olsson, T., Hillert, J. A., & Hedstr\u00f6m, A. K. (2025). Obesity affects disease activity and progression, cognitive functioning, and quality of life in people with multiple sclerosis. Neurology Neuroimmunology & Neuroinflammation, 12(1), e200334. https:\/\/doi.org\/10.1212\/nxi.0000000000200334","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"6","key":"379_CR76","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1177\/13524585231164296","volume":"29","author":"R Palladino","year":"2023","unstructured":"Palladino, R., Marrie, R. A., Majeed, A., & Chataway, J. (2023). Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study. Multiple Sclerosis Journal, 29(6), 671\u2013679. https:\/\/doi.org\/10.1177\/13524585231164296","journal-title":"Multiple Sclerosis Journal"},{"issue":"9","key":"379_CR77","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40265-021-01526-w","volume":"81","author":"N Huntemann","year":"2021","unstructured":"Huntemann, N., Rolfes, L., Pawlitzki, M., Ruck, T., Pfeuffer, S., Wiendl, H., & Meuth, S. G. (2021). Failed, interrupted, or inconclusive trials on neuroprotective and neuroregenerative treatment strategies in multiple sclerosis: Update 2015\u20132020. Drugs, 81(9), 1031\u20131063. https:\/\/doi.org\/10.1007\/s40265-021-01526-w","journal-title":"Drugs"},{"issue":"9936","key":"379_CR78","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/s0140-6736(13)62242-4","volume":"383","author":"J Chataway","year":"2014","unstructured":"Chataway, J., Schuerer, N., Alsanousi, A., Chan, D., MacManus, D., Hunter, K., Anderson, V., Bangham, C. R., Clegg, S., Nielsen, C., & Fox, N. C. (2014). Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet, 383(9936), 2213\u20132221. https:\/\/doi.org\/10.1016\/s0140-6736(13)62242-4","journal-title":"Lancet"},{"issue":"9","key":"379_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-086414","volume":"14","author":"J Blackstone","year":"2024","unstructured":"Blackstone, J., Williams, T., Nicholas, J. M., Bordea, E., De Angelis, F., Bianchi, A., Calvi, A., Doshi, A., John, N., Mangion, S. A., & Wade, C. (2024). Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): Protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. British Medical Journal Open, 14(9), e086414. https:\/\/doi.org\/10.1136\/bmjopen-2024-086414","journal-title":"British Medical Journal Open"},{"key":"379_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.07.007","volume":"276","author":"J Khambhati","year":"2018","unstructured":"Khambhati, J., Engels, M., Allard-Ratick, M., Sandesara, P. B., Quyyumi, A. A., & Sperling, L. (2018). Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. Atherosclerosis, 276, 1\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.07.007","journal-title":"Atherosclerosis"},{"issue":"4","key":"379_CR81","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/qjmed\/hcab207","volume":"116","author":"CA Bonfiglio","year":"2021","unstructured":"Bonfiglio, C. A., Weber, C., Atzler, D., & Lutgens, E. (2021). Immunotherapy and cardiovascular diseases: novel avenues for immunotherapeutic approaches. QJM: An International Journal of Medicine, 116(4), 271\u2013278. https:\/\/doi.org\/10.1093\/qjmed\/hcab207","journal-title":"QJM: An International Journal of Medicine"},{"issue":"29","key":"379_CR82","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/jco.21.01808","volume":"40","author":"D Laenens","year":"2022","unstructured":"Laenens, D., Yu, Y., Santens, B., Jacobs, J., Beuselinck, B., Bechter, O., Wauters, E., Staessen, J., Janssens, S., & Van Aelst, L. (2022). Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. Journal of Clinical Oncology, 40(29), 3430\u20133438. https:\/\/doi.org\/10.1200\/jco.21.01808","journal-title":"Journal of Clinical Oncology"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00379-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00379-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00379-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T23:02:23Z","timestamp":1745190143000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-025-00379-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["379"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00379-y","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AM: received honoraria for lecturing and consulting from Alexion and Roche and travel reimbursements from Alexion. SP: received honoraria for lecturing and consulting from Sanofi-Avents, Merck Healthcare, Biogen, Novartis Pharma, Roche, Alexion and Hexal, travel reimbursements from Sanofi-Aventis, Merck Healthcare, Novartis Pharma, Roche, and Biogen, and research funding from DIAMED, Merck Healthcare, Novartis Pharma, Sanofi-Aventis and Biogen. SGM: received honoraria for lecturing, travel expenses and for attending meetings from Academy 2, Argenx, Alexion, Almirall, Amicus Therapeutics Germany, AstraZeneca, Bayer Health Care, Biogen, BioNtech, BMS, Celgene, Datamed, Demecan, Desitin, Diamed, Diaplan, DPmed, Gen Medicine and Healthcare products, Genzyme, Hexal AG, IGES, Impulze GmbH, Janssen Cilag, KW Medipoint, MedDay Pharmaceuticals, Medmile, Merck Serono, MICE, Mylan, Neuraxpharm, Neuropoint, Novartis, Novo Nordisk, ONO Pharma, Oxford PharmaGenesis, QuintilesIMS, Roche, Sanofi, STADA, Chugai Pharma, Teva, UCB, Viatris, Wings for Life international and Xcenda. He received research support from Alexion, Almirall, Amicus Therapeutics Germany, Argenx, Bayer Vital GmbH, BGP Products Operations (Viatris Company), Biogen, BMS, Demecan, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Hexal, Janssen, Merck Serono, Novartis, Novo Nordisk Pharma, ONO Pharma, Roche and Teva.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}